Article Abstract

Abiraterone survival benefit is independent of pain, prostate-specific antigen and Gleason sum in men with chemo-naïve metastatic castration-resistant prostate cancer (analysis of COU-AA-302)

Authors: Panagiotis J. Vlachostergios, Giuseppe Galletti, Scott T. Tagawa

Abstract

Advanced prostate cancer (PC), including metastatic castration-resistant prostate cancer (mCRPC) represents the lethal form of PC, yet remains largely dependent on androgen signaling (1). Abiraterone acetate (AA) is a steroid 17-hydroxylase/C17,20-lyase (CYP17) inhibitor targeting testicular, adrenal and intratumoral androgen production.